

PRESS RELEASE**Metropolis Healthcare Limited Launches Centre of Genomics to Scale Precision Diagnostics and Advance Research in India**

~ Deploys *Illumina's NovaSeq™ X Series* to strengthen genomic research and broaden access to advanced insights.

~ Backed by **two CAP-accredited genomics labs in Delhi NCR and Mumbai**, supporting **oncology, reproductive health, neurology, transplant immunology, and rare diseases** ~

~ Plans to expand genomic portfolio to 500+ advanced tests across key clinical specialties ~

National, January 13, 2026: Ameera Shah-led Metropolis Healthcare Limited (**NSE: METROPOLIS | BSE: 542650**), India's second-largest and the most trusted pathology laboratory chain, today announced the launch of its **Centre of Genomics**, marking a significant step in scaling its long-standing capabilities in advanced genomics, molecular diagnostics, precision medicine, and genomic research. The Centre of Genomics is designed to deliver clinically actionable genomic insights across the care continuum, supporting multiple high-impact clinical specialties.

Over the years, Metropolis has built a strong foundation in advanced genomics, with a particular focus on precision oncology anchored by its Global Reference Laboratory in Mumbai. Following the integration of Core Diagnostics' specialised genomics laboratory in the Delhi NCR region, these complementary capabilities have been unified to operate as CAP-accredited national referral laboratories for genomics, forming the backbone of the Centre of Genomics. This integrated model brings together a broad portfolio of NGS-based assays, robust bioinformatics and interpretation capabilities, and deep scientific and clinical expertise.

As part of the Centre's technology backbone, Metropolis has augmented its existing sequencing infrastructure with the deployment of **Illumina's NovaSeq™ X Series** for research purposes. The NovaSeq™ X system features Illumina's cutting-edge XLEAP-SBS™ chemistry, offering unmatched throughput, accuracy, and sustainability. The NovaSeq™ X Plus can generate more than 20,000 whole genomes per year, more than double the throughput of Illumina's previous sequencers. Its unprecedented speed, scale, and accuracy push the limits of what is possible in genetic sequencing, enabling users to unlock discoveries and advancements that were previously beyond reach.

Beyond the newly deployed NovaSeq™ X Series, the Centre of Genomics is supported by an existing, multi-platform NGS infrastructure already operational across Metropolis' key genomics hubs. The Centre of Genomics brings together multidisciplinary teams of molecular pathologists, genomic scientists, researchers, bioinformaticians, and certified genetic counsellors to ensure that complex genomic data is translated into clear, reliable, and clinically meaningful insights for patient care.

Commenting on the launch, **Ms. Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited**, said: *"Genomics marks a decisive inflection point for diagnostics in India, expanding the role of laboratories from disease detection to risk prediction, therapy personalisation, and long-term disease management. As genomics increasingly informs lifelong medical decisions, leadership in this space is defined not by adoption alone, but by rigorous validation, deep expertise, quality assurance, and clinical responsibility. Through the Centre of Genomics, we bring together orthogonal, cross-platform technologies with advanced data analytics and AI-driven trend correlations. Supported by strong clinical stewardship from subject-matter experts, a multi-specialty*



Medical Advisory Board, and dedicated clinical support teams, this approach enables us to build one of India’s most comprehensive and clinically integrated genomic diagnostic platforms.”

Dr. Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Limited, said: *“The Centre of Genomics has been designed to translate advanced genomic science into actionable clinical decision-making across high-impact disease areas, including oncology, reproductive health, neurology, transplant immunology, and rare diseases. Our differentiation lies in rigorous validation, multi-platform testing, and deep clinical integration, ensuring results are reliable and clinically meaningful. With over 220 validated genomic tests and a clear roadmap to expand beyond 500 assays over the next two to three years, the Centre of Genomics is benchmarked against leading global genomic laboratories in terms of breadth, quality, and clinical integration, while remaining closely aligned to India-specific disease patterns and care pathways.”*

“As Illumina expands its presence in India, our mission is to make advanced sequencing technologies more accessible across the country,” said **Suchita Dayanand, Country Head – India (Commercial), Illumina.** *“The NovaSeq™ X Series demonstrates our leadership in next-generation sequencing, and we are proud to see Metropolis Healthcare leveraging our most sustainable high-throughput sequencer to drive transformative research and innovation.”*

Beyond portfolio expansion, the Centre of Genomics is envisioned as a platform for continuous test development, AI-enabled analytics, and deeper digital integration—strengthening reporting quality, operational efficiency, and clinical impact. With B2B operations spanning multiple countries and active engagement in pharmaceutical programs and clinical trials, Metropolis is positioning the **Centre of Genomics** as a strategic partner for global research, companion diagnostics, and precision-led drug development.

About Metropolis Healthcare Limited

Established in 1981, Metropolis Healthcare Limited is India’s second-largest diagnostic chain, led by visionary leader Ms. Ameera Shah, Promoter and Executive Chairperson. With over four decades of excellence, Metropolis has been a pioneer in delivering best-in-class diagnostic services to patients, healthcare providers, and corporates across India and Africa. The company’s extensive footprint spans 28 states, 7 Union Territories, and over 750 towns in India, supported by a robust network of more than 220 laboratories, 4,450+ service centers, and over 10,000 touchpoints.

Each year, Metropolis serves millions of individuals by providing actionable health insights that empower better clinical outcomes. Metropolis offers a comprehensive range of more than 4,000 tests and profiles, including advanced tests for diagnosing cancer, neurological disorders, infectious diseases, and various genetic abnormalities. The company’s commitment to quality and accuracy is reinforced by its consistent CAP proficiency score of over 99% for the past decade, placing it among the top 1% of laboratories worldwide for quality assurance. The Metropolis philosophy is built on the pillars of technological superiority, a warm, patient-centric approach, and reliable diagnostic reports. For more information, please visit www.metropolisindia.com or click on [Twitter](#), [Facebook](#), or [LinkedIn](#)

About Illumina

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on [X](#), [Facebook](#), [LinkedIn](#), [Instagram](#), [TikTok](#), and [YouTube](#).

MEDIA CONTACTS:

<p>Jeyasingh Balakrishnan Metropolis Corporate Communications Mob: +91 9833836185 Email: jeyasingh.b@metropolisindia.com</p>	<p>Aniket Singh Saran AvianWE (Metropolis' PR Partner) Mob: + 91 9560476715 Email: aniket@avianwe.com</p>
<p>Aarti Deepak Taneja Illumina Inc., Corporate Communications Phone: +91 7291988760 Email: ataneja@illumina.com</p>	